Antheia, Inc.

Next up in our #MeetTheTeam series, we’re pleased to introduce Ben Kotopka, Director of Data Science at Antheia. As our R&D team is constantly generating and collecting data, a comprehensive data strategy is essential -- without one, it is nearly impossible to successfully scale a new technology. Read more on what led Ben to work in data science and his views on this emerging field: https://bit.ly/474bucR #Antheia #DataScience #SyntheticBiology #PharmaSupplyChains

This week, we had the pleasure of hosting a group of college students and graduates from the MelanInScience Tech Connect Summer Program at Antheia for a tour of our labs and a discussion with our team to learn about synthetic biology. MelanInScience was founded by the incredible Carmen Banks, PhD to build a brighter and more inclusive future for STEM and increase representation of marginalized communities in science. MelanInSience’s programs provide invaluable knowledge, mentorship, and resources to participants to help them pursue their own unique journey in STEM. We loved meeting this group of future scientists and can’t wait to see what they do! Learn more about MelanInScience: https://lnkd.in/eEqr6w32

The #Antheia team closed out the week with an epic game of water balloon toss at our family picnic! The competition was fierce, the grill was hot, and the vibes were high at Antheia HQ yesterday.

Antheia’s co-founder & CSO, Dr. Kristy Hawkins and COO, Zack McGahey recently sat down with Genetic Engineering & Biotechnology News to discuss Antheia’s proven approach of scaling novel biomanufacturing processes for critical pharmaceutical ingredients. For Antheia, scaling up means collaborating with industry partners, securing manufacturing capacity, and working with government bodies to onshore and stabilize pharmaceutical supply chains. On the heels of the company’s latest project agreement with the BioMaP-Consortium | Biopharmaceutical Manufacturing Preparedness Consortium, McGahey stated it perfectly: “We truly believe that the future of this technology should be here in the United States.” Read more about how Antheia is using synthetic biology to address supply chain cohesion, surety, and onshoring: https://bit.ly/46E67kv

Our latest project agreement with the BioMaP-Consortium | Biopharmaceutical Manufacturing Preparedness Consortium reinforces the bold vision that is the foundation of Antheia: synthetic biology is the future of pharmaceutical manufacturing.   We have always seen this technology as transformative for critical supply chains and this project will lay the groundwork for onshoring pharma to the U.S. with next-gen biomanufacturing processes. Paired with the matching support from new investors, including IQT (In-Q-Tel) and Echo, today's news is a milestone for Antheia that I'm proud of – I look forward to seeing what we will accomplish together.  

We're proud to announce $17M in funding through a project agreement with the BioMaP-Consortium | Biopharmaceutical Manufacturing Preparedness Consortium and matching support from new strategic investors, including IQT (In-Q-Tel) and Echo. The combined funding will support onshoring production of critical pharmaceutical ingredients to the U.S. and accelerating our commercialization strategy. Today’s announcement signals an important moment in Antheia’s commercial trajectory and a close alignment with the U.S. government’s priorities, as we pursue the shared goal of transforming pharmaceutical supply chains, so that essential medicines are reliably available to everyone who needs them. Learn more: https://bit.ly/3LAm3dG #Antheia #BioMaP #Funding #Biomanufacturing #PharmaSupplyChains

There are many potential pitfalls in our pharmaceutical supply chains and with more than 130 drugs currently in shortage, developing innovative and enduring solutions to end these shortages is more critical than ever. In our latest blog, we dissect the pharmaceutical manufacturing landscape and the root causes behind drug shortages. Read more on how biomanufacturing can transform global pharma supply chains to be more resilient, reliable, and efficient: https://bit.ly/3VSXVsR #Antheia #Biomanufacturing #PharmaSupplyChains #DrugShortages

In case you missed Dr. Kristy Hawkins' mainstage talk at SynBioBeta earlier this year, you can now catch the replay on our website. Tune in to learn how our team is rapidly scaling highly engineered strains from the lab bench to commercial scale and transforming pharma supply chains. #SynBioBeta #Biomanufacturing #SyntheticBiology #PharmaSupplyChains https://bit.ly/45qKVxX

Happening later today at #BIO2024 in San Diego: Antheia’s CEO and co-founder Dr. Christina Smolke will join Ginkgo Bioworks, Inc., BASF, and Geno on a panel to discuss how biotech can build more resilient supply chains while addressing persistent sustainability challenges across critical industries like pharma and agriculture. Catch the session at 4:15pm PT: https://bit.ly/3Kxp5zc #Antheia #Biotechnology #Biomanufacturing #Pharma #Sustainability

Next up in our #MeetTheTeam series is a fascinating Q&A with Pavel Aronov, Senior Director, Bioanalytics. Pavel’s journey included stops at Stanford’s mass spectrometry lab and multiple food startups before he joined Antheia. His team focuses on analytical chemistry, which involves understanding the quantitative composition of matter. Key questions that Pavel answers include: are we making the right product, is it pure enough, and is the measurement accurate? This work plays a crucial role in our commercial strategy as we scale up production of our biosynthetic KSMs and APIs. Read more about Pavel’s work and what drew him to Antheia: https://bit.ly/3KqABfw #Antheia #PharmaSupplyChain #Bioanalytics #SyntheticBiology